What dose of external-beam radiation is high enough for prostate cancer?
about
Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancerEvidence based radiation oncology with existing technologySalvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy.Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysisStereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patientsHypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study.The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mixRandomized trial of hypofractionated external-beam radiotherapy for prostate cancer.The Dose Verification System (DVS) for cancer patients receiving radiation therapy.A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.Does treatment duration affect outcome after radiotherapy for prostate cancer?Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.Defining a dose-response relationship for prostate external beam radiotherapy.Improving outcomes in high-risk prostate cancer with radiotherapy.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment.The role of iron oxide nanoparticles in the radiosensitization of human prostate carcinoma cell line DU145 at megavoltage radiation energies.Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review.CD44 is a biomarker associated with human prostate cancer radiation sensitivity.CyberKnife radiosurgery for prostate cancer.Proton-beam therapy: are physicists ignoring clinical realities?A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression.Is it time to reevaluate definitive therapy in prostate cancer?Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification.Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy.Planning and implementing an implanted fiducial programme for prostate cancer radiation therapy.Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.Assessing prostate, bladder and rectal doses during image guided radiation therapy — need for plan adaptation?Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer*.Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy
P2860
Q33415382-8B390B8B-AD90-4D7A-8C29-3F3DBE639149Q33922185-32C9111D-ACD0-40C8-BBF8-80378D2DF6D9Q34355171-D6590CA4-353B-4A05-9178-07D54B6EAB85Q36156751-A17B26C4-1443-4ECC-8E11-5DB0A7A699FDQ36214859-CCEC696F-0216-40AA-ADE3-62C0A3A94C05Q36426682-3786990E-936F-4D71-B373-A5BD17B2A7ADQ36726326-4074039D-9E59-4EB9-8C74-AFBD6B2CF15FQ36798868-9773A7EA-71C0-4989-B8AC-D45C50E72291Q36990405-BB963E96-CF87-463A-86E8-1FF320D282F9Q37065578-79A2C05D-4245-49C0-9983-621561228F2AQ37249348-16AFEE84-BEAF-4AC2-A851-BE27A9CF2F97Q37331729-05466BD0-8D50-419E-87C3-EB1E89B56985Q37386325-C1FCBB0E-5F48-4493-8A40-CBA2F60F1AA6Q37389911-B6A9F741-9570-49FC-A08A-41AC6D803255Q37427059-C24C41FF-479A-493D-951E-844D3967C632Q38095668-80C15672-7B60-4AAB-8BA6-DA4DA81BBFC9Q38177806-F1CE22BD-7374-4369-882E-98193F0A8929Q38180344-CE26227D-24AF-468A-8731-15E4513CB0C8Q38927480-53A6DB38-662C-4E2D-A50C-F870FE09640EQ39029320-9CACA914-34BD-4B91-92D2-FED3B4667B1CQ39070920-3CCE29C9-170E-46F9-B918-2CCC9B7D5955Q39422186-E9DAB22C-1121-4901-B28B-8CE124E432E7Q39467150-D1317706-74FB-4194-9F8F-77923102882EQ39841215-5990C433-EB50-43EF-B5A8-A1F70A16E817Q40807241-58872B57-87DE-4E96-98AA-77E727AC9828Q41887636-0743445E-E00E-4B85-B30F-059FADA68B6DQ41997352-9B593B20-10BE-4738-ABE0-07507639BD38Q42182229-5048E317-1FB5-4EB4-AC7F-8BB3E645F427Q43116449-BE82C7A3-80DF-444B-90FD-549B9D2A2E22Q44124651-E3F4A6E8-D385-428C-BC53-1E7FBE288CBBQ45182086-AFD2BF34-3FBE-4BD1-BAEE-1EC9E6F21189Q47248668-8D8B0D24-BA57-4CA3-8AFE-34FFFFB621DDQ47905717-2FB4BC1C-815F-4DA8-9AE6-F23A1B609706Q50919717-5BF9D2A0-D250-4D4E-96DD-E8848748ED99Q53143050-E7754CF6-5513-4461-BA33-4C24266B0BB5Q53393213-044F738B-387E-4C28-BC7B-7810591D47E4Q54399617-C355D7F6-4609-47FD-8EB2-601B0D5B6466Q55119815-08359562-F5EF-4664-A692-7C69591842E8Q55434803-4C611E39-5C6E-4460-8345-06F3F30989CFQ57112368-3D031FCB-F92A-4A1D-AE70-EAC268C27D4C
P2860
What dose of external-beam radiation is high enough for prostate cancer?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 March 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What dose of external-beam radiation is high enough for prostate cancer?
@en
What dose of external-beam radiation is high enough for prostate cancer?
@nl
type
label
What dose of external-beam radiation is high enough for prostate cancer?
@en
What dose of external-beam radiation is high enough for prostate cancer?
@nl
prefLabel
What dose of external-beam radiation is high enough for prostate cancer?
@en
What dose of external-beam radiation is high enough for prostate cancer?
@nl
P2093
P2860
P1476
What dose of external-beam radiation is high enough for prostate cancer?
@en
P2093
Alan Pollack
Alexandra L Hanlon
Eric M Horwitz
Gerald E Hanks
Mark K Buyyounouski
Thomas N Eade
P2860
P304
P356
10.1016/J.IJROBP.2007.01.008
P407
P577
2007-03-29T00:00:00Z